Provider review
MEDVidi review
It's a mental-health platform first — GLP-1 is a secondary offering, not the headline
A mental-health platform that also does weight loss: $195 for a first appointment and $159 after, medication billed separately and never priced. It takes no insurance at all right now, so even the visit fee is self-pay.
Straight talk: how we earn — some, not all, of these are affiliate links; start a program through one and we may earn a commission at no extra cost to you. Straight about the rest, too: the write-ups say what each provider is actually worth, and a commission does not change a word of them. Full disclosure here.
On this page
The verdict
MEDVidi's per-visit pricing is transparent and its four named clinicians independently check out via the federal NPI registry, but it's fundamentally a mental-health-first telehealth platform with GLP-1 as a secondary offering, and it doesn't currently accept insurance at all — for the visit fee or the medication.
MEDVidi is not ranked on any of our rankings. This is a standalone read of what the company publishes about itself — the providers we do rank in this category are on our semaglutide provider ranking. Nothing on this page is a performance claim — see the evidence review for what these compounds do and do not do.
Who it is for, and who it is not
A good fit if
- You want a genuinely transparent per-visit price ($195 initial, $159 follow-up) rather than a subscription
- You're also interested in mental-health telehealth from the same platform
- You want four named, NPI-verified clinicians on staff
Look elsewhere if
- You have insurance and want to use it — MEDVidi doesn't currently accept insurance at all, for visits or medication
- You want a dedicated weight-loss platform rather than a mental-health-first one with GLP-1 as a secondary offering
- You want medication pricing disclosed upfront — it's never published
What it actually costs
What they advertise
$195 for an initial appointment and $159 for a follow-up — medication cost is billed separately and not published. MEDVidi does not currently accept insurance for either.
What you actually pay, month to month
Pricing not published for medication; the $195/$159 visit fees are self-pay only, since MEDVidi doesn't currently accept insurance.
Checked live on MEDVidi's own site at https://medvidi.com/ in August 2026. Prices change without notice — confirm before you buy. Work out what a vial actually gives you with our peptide dose calculator.
What is included
The cheapest headline number in this category is often the one with the least attached to it. Here is what MEDVidi bundles in, and what it does not.
Clinician consult
Initial and follow-up visits with named, NPI-verified physicians
Bloodwork / labs
Not published.
Follow-ups and dose changes
Follow-up visits priced separately at $159.
Human support
Four named clinicians on staff.
Injection supplies
Not published.
Shipping
Not published.
Pharmacy, labs and oversight
The pharmacy
Not individually named.
Oversight
Follow-up visits priced separately at $159.
Compounded peptides are not FDA-approved products, and a 503A pharmacy compounds for a named patient while a 503B outsourcing facility manufactures in batches under CGMP. Neither is a quality guarantee on its own — a named facility is simply a fact you can check, and an unnamed “partner pharmacy network” is not. Our guide to verifying a certificate of analysis covers what to ask for.
Where you can get it
Not published — no enumerated list or coverage map found in the pages reachable.
The honest cons
The part they would rather you skipped
MEDVidi's own homepage title and meta framing read 'Online Mental Health Care,' — GLP-1 and weight-loss content is a secondary offering, not the platform's headline product, and it states plainly it doesn't currently accept insurance at all.
- Doesn't currently accept insurance for visits or medication
- Fundamentally a mental-health-first platform with GLP-1 as a secondary offering
- Medication cost is never published, even as a range
- No enumerated state coverage list found
None of this is unique to MEDVidi — the whole category shares it. What we hold against a provider is the part it hides, and the ways vendors hide things are cataloged in our vendor red-flags guide.
How it compares
The providers we rank on our semaglutide provider ranking, in the order that ranking ranks them. MEDVidi is not among them: it is reviewed here, not ranked there, and we would rather show you the comparison than pretend the two are the same thing.
- COCollectiveThe cheapest medication price here, on a membership the headline omits
- CoreAge RxOne price that does not move when your dose does
- BHBodybuilding Health+The deep peptide catalog is gone; the GLP-1 pricing got better
- RxSpan MDOral tablet only, at a real $179 monthly rate
- Enhance MDWrites a flat-price-at-every-dose policy down — and charges near the top for it
- Found HealthInsurance-integrated, unlike every cash-only compounder here — but $99 needs a prepay
- Direct MedsThe plainest price mechanics on either ranking, from a company with an FDA warning letter
- Synergy RxPublishes a starting number, and nothing about what it commits you to
13 more providers rank on our semaglutide provider ranking — see the full ranking. Every provider we review →
Read this before you buy
A provider comparison is half the decision. The other half is whether the compound does anything for you at all — and whether it is allowed where you compete. Growth-hormone secretagogues are banned in tested sport, year-round, and a prescription does not change that.
Facts on this page reflect MEDVidi's own public disclosures when we last checked them, in August 2026. Prices and terms change without notice — confirm on MEDVidi's site before you buy. Provider names and logos on this page identify the company under review; their use does not imply endorsement, sponsorship or affiliation. This page is informational and not medical advice; compounded peptides are not FDA-approved, and growth-hormone secretagogues are banned in tested sport year-round. See our disclosure and editorial policy.